HMGB1 promotes cellular proliferation and invasion, suppresses cellular apoptosis in osteosarcoma
详细信息 查看全文
- 作者：Qingbing Meng ; Jie Zhao ; Hongbing Liu ; Guoyou Zhou ; Wensheng Zhang…
- 关键词：HMGB1 ; Osteosarcoma ; RNA interference
- 刊名：Tumor Biology
- 出版年：2014
- 出版时间：December 2014
- 年：2014
- 卷：35
- 期：12
- 页码：12265-12274
- 全文大小：1,043 KB
- 参考文献：1. Li R, Liu J, Wu H, Liu L, Wang L, Zhang S. TIKI2 suppresses growth of osteosarcoma by targeting Wnt/β-catenin pathway. Mol Cell Biochem. 2014;392:109-6. CrossRef
2. PosthumaDeBoer J, Witlox MA, Kaspers GJ, van Royen BJ. Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature. Clin Exp Metastasis. 2011;28:493-03. CrossRef
3. Bielack SS, Carrle D, Hardes J, Schuck A, Paulussen M. Bone tumors in adolescents and young adults. Curr Treat Options Oncol. 2008;9:67-0. CrossRef
4. Mirabello L, Troisi RJ, Savage SA. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer. 2009;125:229-4. CrossRef
5. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program. Cancer. 2009;115:1531-3. CrossRef
6. He H, Ni J, Huang J. Molecular mechanisms of chemoresistance in osteosarcoma (review). Oncol Lett. 2014;7:1352-2.
7. Chiappetta C, Leopizzi M, Censi F, Puggioni C, Petrozza V, Rocca CD, et al. Correlation of the Rac1/Rhoa pathway with ezrin expression in osteosarcoma. Appl Immunohistochem Mol Morphol. 2014;22:162-0. CrossRef
8. Hou CH, Lin FL, Tong KB, Hou SM, Liu JF. Transforming growth factor alpha promotes osteosarcoma metastasis by ICAM-1 and PI3K/Akt signaling pathway. Biochem Pharmacol. 2014;89:453-3. CrossRef
9. Shen A, Zhang Y, Yang H, Xu R, Huang G. Overexpression of ZEB1 relates to metastasis and invasion in osteosarcoma. J Surg Oncol. 2012;105:830-. CrossRef
10. Tumbar T, Guasch G, Greco V, Blanpain C, Lowry WE, Rendl M, et al. Defining the epithelial stem cell niche in skin. Science. 2004;303:359-3. CrossRef
11. Spradling A, Drummond-Barbosa D, Kai T. Stem cells find their niche. Nature. 2001;414:98-04. CrossRef
12. Hu YH, Yang L, Zhang CG. HMGB1-a as potential target for therapy of hematological malignancies. Zhongguo shi yan xue ye xue za zhi. 2014;22:560-.
13. Srinivasan M, Banerjee S, Palmer A, Zheng G, Chen A, Bosland MC, et al. HMGB1 in hormone-related cancer: a potential therapeutic target. Horm Cancer. 2014;5:127-9. CrossRef
14. Yildirim M, Suren D, Demirpence O, Kaya V, Alikanoglu AS, Bulbuller N, et al. The role of high mobility group box 1 (HMGB1) in colorectal cancer. Med Sci Monit. 2014;20:530-. CrossRef
15. Xiao J, Ding Y, Huang J, Li Q, Liu Y, Ni W, et al. The association of HMGB1 gene with the prognosis of HCC. PLoS ONE. 2014;9:e89097. CrossRef
16. Liu K, Huang J, Xie M, Yu Y, Zhu S, Kang R, et al. MIR34a regulates autophagy and apoptosis by targeting HMGB1 in the retinoblastoma cell. Autophagy. 2014;10:442-2. CrossRef
17. Jia L, Clear A, Liu FT, Matthews J, Uddin N, McCarthy A, et al. Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia. Blood. 2014;123:1709-9. CrossRef
18. Weng H, Deng Y, Xie Y, Liu H, Gong F. Expression and significance of HMGB1, TLR4 and NF-κB p65 in human epidermal tumors. BMC Cancer. 2013;13:311.- 作者单位：Qingbing Meng (1)
Jie Zhao (2)
Hongbing Liu (1)
Guoyou Zhou (1)
Wensheng Zhang (1)
Xingli Xu (1)
Minqian Zheng (1)
1. Orthopedics Department, Yancheng City No.1 People’s Hospital, 16 Yue-He Road, Yancheng, 224005, Jiangsu Province, People’s Republic of China
2. Orthopedics Department, Shanghai Ninth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, People’s Republic of China- 刊物主题：Cancer Research;
- 出版者：Springer Netherlands
- ISSN：1423-0380
- 作者单位：Qingbing Meng (1)
文摘
Osteosarcoma is the most common primary malignant bone tumor in children and adolescents. Unfortunately, treatment failures are common due to the metastasis and chemoresistance, but the underlying molecular mechanism remains unclear. Accumulating evidence indicated that the deregulation of DNA-binding protein high-mobility group box 1 (HMGB1) was associated with the development of cancer. This study aimed to explore the expression of HMGB1 in osteosarcoma tissues and its correlation to the clinical pathology of osteosarcoma and to discuss the role of HMGB1 in the development of osteosarcoma. The results from RT-PCR and Western blot showed that the expression rate of HMGB1 messenger RNA (mRNA) and the expression of HMGB1 in the osteosarcoma tissues were significantly higher than those in normal bone tissue (p--.05), the expression rate of HMGB1 mRNA and the expression of HMGB1 in the carcinoma tissues with positive lung metastasis were significantly higher than those without lung metastasis (p--.05), and with increasing Enneking stage, the expression rate of HMGB1 mRNA and the expression of HMGB1 also increased (p--.05). In order to explore the role of HMGB1 in osteosarcoma, the expression of HMGB1 in the human osteosarcoma MG-63 cell line was downregulated by the technique of RNA interference. Western blot results showed that the protein expression of HMGB1 was significantly decreased in the MG-63 cells from HMGB1-siRNA transfection group (p--.05), which suggested that HMGB1 was successfully downregulated in the MG-63 cells. Then the changes in proliferation, apoptosis, and invasion of MG-63 cells were examined by MTT test, PI staining, annexin V staining, and transwell chamber assay. Results showed that the abilities of proliferation and invasion were suppressed in HMGB1 knockdown MG-63 cells, and the abilities of apoptosis were enhanced in HMGB1 knockdown MG-63 cells. The expression of cyclin D1, MMP-9 was downregulated in HMGB1 knockdown MG-63 cells, and the expression of caspase-3 was upregulated in HMGB1 knockdown MG-63 cells. Taken together, the overexpression of HMGB1 in osteosarcoma might be related to the tumorigenesis, invasion, and metastasis of osteosarcoma, which might be a potential target for the treatment of osteosarcoma.